Correlação entre os fatores prognósticos imunohistoquímicos e a sobrevida em cinco anos de pacientes com diagnóstico de carcinoma da mama em uma instituição pública do estado de Sergipe

Abstract

Breast cancer, despite advances in the modalities of therapy and advances in early diagnosis, continues to be a challenge, as it is the most frequent malignant neoplasm in females with a significant mortality rate. Within this context, one has the research in immunohistochemical markers that aid in the treatment and prognosis of the patients. In this study, a retrospective cohort study was performed with 420 patients from 2011 to 2013. Data from medical records and immunohistochemical reports were collected, which were used to classify patients into subtypes. This study aims to evaluate the survival of patients based on classification in immunohistochemical subtypes. When evaluating the results of the collection, the patients were arranged in 06 subtypes, the most prevalent being the "Luminal B + Triple Positive" with 159 patients (44.41%). Most patients have positive hormone markers around 268 (74.86%), and the presence of these markers is associated with a lower mortality rate, lower than 16% in this study. On the other hand, the presence of the HER2 marker binds to a higher mortality, ranging from 25% to 16%, and the prevalence of HER2 was found in 93 patients (25.97%). Early diagnosis and therapy are essential to reduce patient mortality and morbidity, so markers serve as ways of having a more specific treatment of each subtype.